// App-Quantinova.ai

BSH2020‐PO‐008 : Therapeutic potential of allogeneic gamma delta T cell therapy in relapsed/refractory acute myeloid leukaemia – preliminary data from a phase 1 study

Researchers

Presenter

  • J. Vydra

Principal Investigators

  • K. Curran

  • M. Markova

  • T. Zaremba

  • J. Anderson

  • A. Scott

  • P. Lesny

  • P. Cetkovsky

  • M. Leek

Medical Centers

  • Institute of Hematology and Blood Transfusion, Prague, Czech Republic

  • TC BioPharm, Glasgow

  • UCL Institute of ChildHealth, London, UK

Locations

  • Czech Republic

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Acute myelocytic leukemia

  • Graft-versus-host disease

Biomarkers

  • C reactive protein

  • Cluster of Differentiation 2AP

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT03790072

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved